17:47 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Amgen's Blincyto among negative CHMP opinions

EMA's CHMP released a handful of negative opinions July 27, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC...
20:34 , Jul 27, 2018 |  BC Extra  |  Company News

New Blincyto indication among negative CHMP opinions

EMA's CHMP released a handful of negative opinions Friday, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from...
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
05:15 , Jun 28, 2018 |  BC Extra  |  Financial News

Tricida gains, others dip after upsized IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance Thursday, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each lost ground. All...
22:45 , Jun 20, 2018 |  BC Extra  |  Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief Accounting...
22:45 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis; musculoskeletal Mouse studies suggest inhibiting S1P lyase could help treat osteoporosis and osteopenia. In an osteoprotegerin (OPG)-knockout mouse model of osteoporosis, a tool compound S1P lyase inhibitor increased trabecular bone volume density and a...
17:47 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

CHMP brushes off Radius osteoporosis treatment

EMA's CHMP recommended against approval of Radius' Eladynos abaloparatide-SC to treat osteoporosis in postmenopausal women at increased risk for fracture. Radius said it plans to request a re-examination. Abaloparatide-SC is a subcutaneous peptide analog of parathyroid...
21:59 , Mar 23, 2018 |  BC Extra  |  Company News

CHMP rebuffs Portola's betrixaban, Radius' abaloparatide-SC

EMA's CHMP issued negative opinions on Friday for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from Radius Health Inc. (NASDAQ:RDUS). The committee recommended against approval of Dexxience to prevent venous thromboembolism (VTE) in...
19:05 , Aug 11, 2017 |  BC Week In Review  |  Financial News

Radius prices $300M notes offering

On Aug. 8, Radius Health Inc. (NASDAQ:RDUS) raised $300 million through the sale of 3% senior convertible notes due Sept.1, 2024. The notes have an initial conversion price of $48.81, which is a 21% premium...
17:20 , Aug 11, 2017 |  BioCentury  |  Strategy

Radius’ rookie win

By coming in with a low list price designed to reduce out-of-pocket costs for Medicare patients, Radius Health Inc. also managed the rare feat of getting exclusive placement on Express Scripts Holding Co.’s formulary just...